Research Projects & Grants

Federal

  • Addiction Medicine Fellowship Program, Role: PD/PI, Bureau of Health Professions/Health Resources and Services Administration/DHHS, (07/2020 - 06/2025) Status: Awarded

For Profit Organization

  • A multicenter, global , observational study to collect information on safety and to document the drug utilization of Tecfidera™ (Dimethyl Fumarate)when used in routine medical practice in the treatment of multiple sclerosis (ESTEEM). Protocol Number: 109MS401, Role: PI, Biogen Idec., (11/2022 - 11/2023) Status: Completed
  • A phase 3 open label study to evaluate the long-term safety and tolerability of ALKS 8700 in adults with relapsing remitting multiple sclerosis, Role: PI, Alkermes, Inc., (05/2019 - 05/2020) Status: Completed
  • A dose-blind, multicenter, extension study to determine the long-term safety and efficacy of two doses of BG00012 Monotherapy in subjects with relapsing-remitting multiple sclerosis. Protocol number: 109MS303, version 1 dated 14 October 2008. Investigator's brochure version 6, dated 22 April 2009. Informed consent form version 3 dated 05 February 2009., Role: PI, Biogen Idec., (03/2019 - 03/2020) Status: Completed
  • TYSABRI® Global observational program in safety (TYSABRI). Protocol Number: 101-MS-402 Version 3 dated 07 November 2006. Informed Consent Form Version 3 Dated November 30, 2006., Role: PI, Biogen, Inc., (02/2013 - 02/2014) Status: Completed
  • A multi-center double blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis. Protocol Number: EFC10531, Version #1 (Electronic 2.0) dated 3 July 2008. Investigator's Brochure Edition 11 dated 28 June 2007., Role: PI, Sanofi-Aventis U.S., Inc., (04/2012 - 04/2013) Status: Completed
  • Double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of two doses of oral dalfampridine extended release tablets (5 mg and 10 mg twice daily) in patients with multiple sclerosis. Protocol number: DER-401, version 1.2, dated 01Nov2010. Investigator's brochure version dated 30 April 2010. Informed consent version 1, dated 12/17/2010, Role: PI, Acorda Therapeutics, Inc., (03/2012 - 03/2013) Status: Completed
  • A 6-month, randomized, active comparator, open-label, multi-center study to evaluate patient outcomes, safety and tolerability of fingolimod 0.5 mg/day in patients with relapsing forms of multiple sclerosis who are candidates for MS therapy change from previous disease modifying therapy (EPOC). Protocol number: CFTY720DUS01, version V01, dated 26OCT2010. Informed consent version 1, dated 08/05/10. Investigator's brochure ed. 12 (22Feb2010). Package inserts: avonex dry powder, avonex leuer lock, betaseron, copaxone, extavia, rebif., Role: PI, Novartis Pharmaceuticals Corporation, (12/2011 - 12/2012) Status: Completed
  • A randomized, multicenter, placebo-controlled and active reference (glatiramer acetate) comparison study to evaluate the efficacy and safety of BG00012 in subjects with relapsing-remitting multiple sclerosis. Protocol number: 109MS302, version 2 dated 23 March 2007. Informed consent form version 4, dated 18 April 2007. Investigator's Brochure version 4, dated 28 August2006 and Addendum 1, dated 05 February 2007., Role: PI, Biogen, Inc., (05/2011 - 05/2012) Status: Completed
  • A multicenter, randomized, double placebo-controlled study assessing the add-on effect of oral steroids in relapsing remitting multiple sclerosis subjects treated with Glatiramer Acetate (GA). protocol No: TNC GA MS 2004_01, Role: PI, Teva Neuroscience, (09/2006 - 09/2007) Status: Completed
  • An open-label, prospective parallel cohort study camparing a 90-day Copaxone® adherence enhancement program among persons with multiple sclerosis who participate in Shared Solutions® alone or in partnership with their MS center (protocol PM024) enclosed please find the following for approval; {MS center nursing intervention questionnaire and patient health questionnaire (PHQ-9)}, Role: PI, Teva Neuroscience, (04/2006 - 04/2007) Status: Completed
  • A randomized, rater-blinded, multicenter, parallel-group study comparing the efficacy and safety of Betaseron 250 ug subcutaneously every other day with Avonex 30 ug intramuscularly once per week in relapsing-remiting multiple sclerosis patients previously treated with Avonex. PROTOCOL NUMBER: 307245, Role: PI, Berlex Laboratories Inc., (01/2005 - 01/2006) Status: Completed
  • PNU-95666E: Double-blind, placebo-controlled, dose-response study of tolerability, safety, and efficacy in patients with Parkinson's disease (Protocol M/2760/0009, dated 21 April, 1999), Role: Investigator, Pharmacia, (04/2001 - 04/2002) Status: Completed
  • The clomethizole acute stroke study in acute ischemic stroke (class-I): a double blind, parallel group, multinational, multicenter study of the efficacy and safety of i.v. clomethiazole compared to placebo in patients with acute ischemic stroke. Study code: SA-CMZ-0009 (Protocol dated 08/21/97 and Amendment No. 1 dated 06/23/98)., Role: Investigator, ASTRA (USA), (07/2000 - 07/2001) Status: Completed
  • Titration to response: Analysis of individualized therapy study (TRAITS) Protocol Capss -048, Role: Investigator, Ortho-McNeil Pharmaceutical, (06/1999 - 06/2000) Status: Completed
  • Open-label study to identify the reasons for TASMAR dosage regimen changes in fluctuating Parkinson's disease patients, with follow-up extension, Role: Investigator, Hoffmann-La Roche Inc., (08/1998 - 08/1999) Status: Completed

Internal

  • A study of midodrine in patients with neurogenic orthostatic hypotension. Protocol #20.762-999A, Role: Investigator, LLU Dept. of Neurology, (07/1996 - 07/1997) Status: Completed

Non-Profit Organization

  • Loma Linda University Health Education Consortium Emergency Medicine Residency, Role: PD/PI, Physicians for a Healthy California, (07/2024 - 09/2027) Status: Awarded
  • Loma Linda University Health Education Consortium Family Medicine Residency Program, Role: PD/PI, Physicians for a Healthy California, (07/2024 - 09/2027) Status: Awarded
  • Loma Linda University Health Education Consortium Pediatric Residency Program, Role: PD/PI, Physicians for a Healthy California, (07/2024 - 09/2027) Status: Awarded
  • Loma Linda University Health Education Consortium Internal Medicine Residency Program, Role: PD/PI, Physicians for a Healthy California, (07/2024 - 09/2027) Status: Awarded
  • Loma Linda University Health Education Consortium Obstetrics and Gynecology Residency Program, Role: PD/PI, Physicians for a Healthy California, (07/2024 - 09/2028) Status: Awarded
  • Loma Linda University Health Education Consortium Family Medicine Residency Program FY 2022-2023, Role: PD/PI, Physicians for a Healthy California, (07/2023 - 09/2027) Status: Awarded
  • CalMedForce FY2022-2023: Loma Linda University Health Education Consortium Internal Medicine Residency Program, Role: PD/PI, Physicians for a Healthy California, (07/2023 - 09/2026) Status: Awarded
  • Loma Linda University Health Education Consortium Pediatric Residency Program FY 2022-2023, Role: PD/PI, Physicians for a Healthy California, (07/2023 - 09/2026) Status: Awarded
  • Loma Linda University Health Education Consortium Obstetrics and Gynecology Residency Program FY 2022-2023, Role: PD/PI, Physicians for a Healthy California, (07/2023 - 09/2027) Status: Awarded
  • Loma Linda University Health Education Consortium Internal Medicine/Pediatrics Residency Program FY 2022-2023, Role: PD/PI, Physicians for a Healthy California, (07/2023 - 09/2027) Status: Awarded
  • Loma Linda University Health Education Consortium Emergency Medicine Residency FY 2022-2023, Role: PD/PI, Physicians for a Healthy California, (01/2023 - 09/2026) Status: Awarded
  • CalMed Force Prop 56 Emergency Medicine/Loma Linda University Health Education Consortium Emergency Medicine Residency Program, Role: PD/PI, Physicians for a Healthy California, (07/2021 - 09/2024) Status: Closed
  • CalMed Force Internal Medicine/Loma Linda University Health Education Consortium Internal Medicine Residency Program, Role: PD/PI, Physicians for a Healthy California, (07/2021 - 09/2024) Status: Closed
  • CalMed Force OBGYN/Loma Linda University Health Education Consortium Obstetrics and Gynecology Residency Program, Role: PD/PI, Physicians for a Healthy California, (07/2021 - 09/2025) Status: Awarded
  • CalMed Force Pediatrics/ Loma Linda University Health Education Consortium Pediatric Residency Program, Role: PD/PI, Physicians for a Healthy California, (07/2021 - 09/2024) Status: Closed
  • CalMed Force Family Medicine/ Loma Linda University Health Education Consortium Family Medicine Residency Program, Role: PD/PI, Physicians for a Healthy California, (07/2021 - 09/2024) Status: Closed
  • CalMed Force Prop 56- Department of Obstetrics and Gynecology, Role: PD/PI, Physicians for a Healthy California, (07/2020 - 09/2023) Status: Closed
  • CalMed Force Prop 56- Department of Pediatrics, Role: PD/PI, Physicians for a Healthy California, (07/2020 - 09/2023) Status: Closed
  • CalMed Force Prop 56- Department of Internal Medicine, Role: PD/PI, Physicians for a Healthy California, (07/2020 - 09/2023) Status: Closed
  • CalMed Force Prop 56- Department of Emergency Medicine, Role: PD/PI, Physicians for a Healthy California, (07/2020 - 09/2023) Status: Closed
  • CalMed Force Prop 56- Department of Family Medicine, Role: PD/PI, Physicians for a Healthy California, (07/2020 - 09/2023) Status: Closed
  • (CDA) - Evobrutinib vs Teriflunomide Trial, a Phase III registrational study evaluating treatment in Subjects with relapsing multiple sclerosis, Role: PD/PI, IQVIA RDS Inc., Status: Awarded

State

  • Pediatric Primary Care Training at Children's Hospital, Role: PD/PI, Office of Statewide Health Planning and Development, (02/2020 - 06/2021) Status: Awarded